REMI (Remedent) EBIT: $-0.24 Mil (TTM As of Dec. 2020)


REMI Remedent Inc REMI
12 GF Score
Price $0.00
View Full Analysis

What is Remedent EBIT?

Remedent REMI +16.67% 12 EBIT is $-0.24 Mil as of Dec. 2020. GuruFocus rates REMI with a GF Score™ of 12/100.

Remedent's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2020 was $0.10 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2020 was $-0.24 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Remedent's annualized ROC % for the quarter that ended in Dec. 2020 was 0.79%. Remedent's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2020 was 741.82%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Remedent's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2020 was -1,678.57%.

Remedent  (OTCPK:REMI) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Remedent's annualized ROC % for the quarter that ended in Dec. 2020 is calculated as:

ROC % (Q: Dec. 2020 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2020 ) + Invested Capital (Q: Dec. 2020 ))/ count )
=0.056 * ( 1 - 1.98% )/( (6.848 + 7.011)/ 2 )
=0.0548912/6.9295
=0.79 %

where

Invested Capital(Q: Sep. 2020 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=7.475 - 2.786 - ( 0.128 - max(0, 2.904 - 0.745+0.128))
=6.848

Invested Capital(Q: Dec. 2020 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=7.563 - 2.764 - ( 0.083 - max(0, 2.912 - 0.7+0.083))
=7.011

Note: The Operating Income data used here is four times the quarterly (Dec. 2020) data.

2. Joel Greenblatt's definition of Return on Capital:

Remedent's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2020 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2020 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2020  Q: Dec. 2020
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=0.408/( ( (0.035 + max(-2.287, 0)) + (0.075 + max(-2.295, 0)) )/ 2 )
=0.408/( ( 0.035 + 0.075 )/ 2 )
=0.408/0.055
=741.82 %

where Working Capital is:

Working Capital(Q: Sep. 2020 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.401 + 0.113 + 0.103) - (2.786 + 0.113 + 0.0049999999999999)
=-2.287

Working Capital(Q: Dec. 2020 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.475 + 0.108 + 0.034) - (2.764 + 0.142 + 0.0060000000000002)
=-2.295

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2020) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Remedent's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2020 )
=-0.235/0.014
=-1,678.57 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Remedent EBIT Related Terms

Remedent EBIT Historical Data

* Premium members only.

The historical data trend for Remedent's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Remedent EBIT Chart

Remedent Annual Data
Trend Mar11 Mar12 Mar13 Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.26 0.86 -0.03 2.13 -0.84

Remedent Quarterly Data
Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.16 -0.35 0.01 0.00 0.10

REMI vs SECI, RSCF, OZSC: EBIT Comparison

For the Medical Instruments & Supplies subindustry, Remedent's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Remedent EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Remedent's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Remedent's EV-to-EBIT falls into.


REMI
12GF Score
Remedent Inc REMI
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Remedent EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.24 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-0.24 Mil mean?
Remedent (REMI) has a EBIT of $-0.24 Mil as of Dec. 2020. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Remedent.
Is Remedent's EBIT too high?
Remedent's current EBIT is $-0.24 Mil. Overall, Remedent has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Remedent's EBIT compare to SECI and RSCF?
Remedent's EBIT of $-0.24 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Remedent. Remedent's current EBIT is $-0.24 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Remedent stock overvalued right now?
Remedent (REMI) has a current EBIT of $-0.24 Mil. The current EBIT is $-0.24 Mil. Remedent's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Remedent (REMI), the current EBIT is $-0.24 Mil as of Dec. 2020. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Remedent Business Description

Address Zuiderlaan 1-3, Bus 8, Ghent, BEL, 9000
Remedent Inc is a manufacturer of cosmetic dentistry products in Europe. The company is engaged in the research, development, and manufacturing of oral care and cosmetic dentistry products. It designs, develops, manufactures, and distributes cosmetic dentistry products, including a full line of professional dental products that are distributed in Europe, Asia, the Middle East, and the United States.
12GF Score

Get the complete analysis for REMI

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price